Multicenter, Controlled, Open-Label Extension (OLE) Study To Assess the Long-Term Safety and Efficacy of AMG 145 (study 20110110)

Published: 10-10-2011
Last updated: 01-05-2024

Primary: Longterm safety and tolerability of AMG 145.Secondary: Longterm efficacy of AMG 145.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Lipid metabolism disorders
Study type	Interventional

Summary

ID

NL-OMON40037

Source
ToetsingOnline

Brief title
AMG20110110 (OSLER)

Condition

- Lipid metabolism disorders

Synonym
hypercholesterolaemia; elevated cholesterol

Research involving
Human

Sponsors and support

Primary sponsor: Amgen
Source(s) of monetary or material Support: Amgen BV

Intervention

Keyword: AMG 145, efficacy, Hypercholesterolaemia, safety

Outcome measures

Primary outcome

Adverse events.

Secondary outcome

LDL-C, non-HDL-C, ApoB, total cholesterol/HDL-C ratio, ApoB/Apo A1 ratio in

week 24 and 52.

Study description

Background summary

AMG 145 is a fully human monoclonal immunoglobulin (Ig) G2 that binds specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and prevents the interaction of PCSK9 with the LDL receptor. AMG 145 caused a dose-related inhibition of PCSK9 binding to the LDL receptor and of the PCSK9-mediated reduction in low-density lipoprotein (LDL) uptake in hepatic cells. Treatment of cells with a combination of AMG 145 and statin increased LDL receptor protein levels more than treatment with either alone. Single administrations in humans produced decreases in mean LDL-C with subsequent returns to baseline. Across the dose groups, the decreases were dose-related. Overall, AMG 145 appeared to be well tolerated at the IV and SC doses administered in this FIH study. Incidences of overall adverse events and treatment-related adverse events did not differ notably between treatment groups.
This study is being conducted to gather information on the long-term safety and efficacy of AMG 145. Many of the subjects in the parent Phase 2 studies are in a high unmet medical need group such as heterozygous familial hypercholesterolemia, or statin intolerance, or have failed to reach goal with available therapies. For these populations, participation in this open label extension will provide close medical supervision via healthcare professionals while on current standard of care therapies and an opportunity to receive an additional therapeutic option for LDL-C lowering.

Study objective

Primary: Longterm safety and tolerability of AMG 145.
Secondary: Longterm efficacy of AMG 145.

Study design

Multicenter open-label controlled phase II parallel-group extension study.
Randomisation (2:1) to:
* Standard therapy plus AMG 145 420 mg (s.c. injections every 4 weeks)
* Standard therapy.
1st 12 weeks standard therapy as during previous study and blinded LDL-C values. After 12 weeks unblinding and option to adjust standard therapy.
Study duration 1 year.
Approx. 1600 patients.

Intervention

Treatment with AMG 145.

Study burden and risks

Risk: Adverse effects of study medication.
Burden: Max. study duration approx. 5 year (or until AMG 145 is commercially available). monthly visits, duration approx. 1-2 h (control group 5 visits and 9 phone calls in 1st year). 6 fasting visits in 1 st year; thereafter every 3 months.
12 SC injections (6 mL) for experimental group in 1st year. Thereafter monthly for all participants.
Physical examination 2x.
Blood tests 1st year for experimental group 7x, control group 6x 30-50 mL/occasion. After 1st year every 3 months. Plus samples for biomarker development, 60 mL in total.
Steroid substudy: optional, 4x blood sample.
Pregnancy test (if relevant) 3-4x in 1st year, thereafter very 6 months.
ECG 1x.

Contacts

Public
Amgen

Postbus 3345
Breda 4800 DH
NL
Scientific

Amgen

Postbus 3345
Breda 4800 DH
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

* Completed a qualifying AMG 145 parent study protocol.

Exclusion criteria

* Experienced a treatment-related serious adverse event in the parent study with AMG 145.
* Pregnancy, inadequate contraception, breast feeding.

Study design

Design

Study phase:	2
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Open (masking not used)

Control:	Active
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	19-01-2012
Enrollment:	25
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	AMG 145
Generic name:	AMG 145

Ethics review

Approved WMO Date:	10-10-2011
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO Date:	23-12-2011
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO Date:	16-02-2012
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	20-02-2012
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	27-02-2012

Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	08-03-2012
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	21-12-2012
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	17-05-2013
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	07-06-2013
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	04-03-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	13-03-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	16-05-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	18-08-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	04-12-2014

Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	19-12-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	23-04-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	06-05-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	25-11-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	27-11-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	24-05-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	25-05-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	27-07-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	28-07-2016

Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	02-08-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	27-09-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	04-11-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	16-11-2016
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	25-09-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	27-09-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	26-10-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	01-11-2017
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
Other	clinicaltrials.gov, regsitratienummer n.n.b.
EudraCT	EUCTR2011□001915□29-NL
CCMO	NL38031.018.11